Levosimendan Win Medica (Levosimendan)

Levosimendan enhances the sensitivity of cardiac troponin C to calcium, which increases myocardial contractility without raising intracellular calcium levels. Additionally, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and lowering after‑load, together supporting overall cardiac performance.

The dosing regimen for Levosimendan Win Medica is determined by the prescribing clinician based on the patient’s clinical status, severity of heart failure, and response to therapy. Specific infusion rates and duration are individualized and should follow local prescribing guidelines.

Safety data for levosimendan during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Unlike traditional inotropes like dobutamine, levosimendan increases contractility by sensitizing troponin C rather than raising intracellular calcium, which may reduce the risk of calcium‑mediated toxicity. It also provides vasodilatory effects through potassium‑channel activation, offering combined inotropic and after‑load‑reducing benefits.

Levosimendan Win Medica must be stored at 2‑8 °C in a refrigerator, protected from light. The solution should not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

The medication is given as an intravenous infusion. After reconstitution, the solution is administered through a controlled infusion pump, allowing precise rate adjustments based on the patient’s hemodynamic response and clinical monitoring.

The most serious adverse events include severe hypotension, ventricular arrhythmias, and myocardial ischemia. These risks require continuous blood‑pressure and ECG monitoring during infusion, and prompt intervention if significant hemodynamic instability occurs.

Levosimendan is contraindicated in patients with severe hypotension, obstructive cardiac lesions such as severe aortic stenosis, or known hypersensitivity to the drug. Caution is also advised in individuals with significant renal or hepatic impairment, unless dose adjustments are made under medical supervision.